References
- Banga, A.K. and Chien, Y.W. (1998) “Iontophoretic delivery of drugs: fundamentals, developments and biomedical applications”, J. Control Rel. 7, 1–24.
- Bellantone, N.H., Rim, S., Francoeur, M.L. and Rasadi, B. (1986) “Enhanced percutaneous absorption via iontophoresis I. Evaluation of an in vitro system and transport of model compounds”, Int. J. Pharm. 30, 63–72.
- Burnette, R.R. and Ongipattanakul, B. (1987) “Characterization of the permselective properties of excised human skin during ionto- phoresis”, J. Pharm. Sci. 76(1987),765–773.
- Fatouros, D.G. and Bouwstra, J.A. (2003) “Iontophoretic delivery maleate across human stratum corneum in vitro”, Eur. J. Pharm. Sci., submitted to.
- van der Geest, R., Danhof, M. and Bodde, H.E. (1997) “Iontophoretic delivery of Apomorphine: in vitro optimization and validation”, Pharm. Res. 14, 1797–1802.
- van der Geest, R., Danhof, D. and Bodde, H.E. (1998) “Validation and testing of a new iontophoretic continuous flow through transport cell”, J. Control Rel. 51(1),85–91, 23.
- Goodman and Gilman (1990) In: Goodman Gilman, Al., Rall, T.W., Nies, A.S. and Taylor, P., eds, The Pharmacological Basis of Therapeutics, 8th ed. (Pergamon Press Inc.), p 1170.
- Green, P.G. (1996) “Iontophoretic delivery of peptide drugs”, J. Control Rel. 41(1996),33–48.
- Guy, R.H. and Hadgraft, J. (1989) “Selection of drug candidates for transdermal delivery”, In: Hadgraft, J. and Guy, R.H., eds, Transdermal Drug Delivery (Marcel Dekker), pp 59–81.
- Hirvonen, J. and Guy, R.H. (1997) “Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances”, Pharm. Res. 14, 1258–1263.
- Hirvonen, J., Murtomaki, L. and Konturi, K. (1998) “Experimental verification of the mechanistic model for transdermal transport including iontophoresis”, J. Control Rel. 56, 169–174.
- Ishizaki, T., Tawara, K., Oyama, Y. and Nakaya, H. (1978) “Clinical pharmacologic observations on Timolol. II. Antihypertensive effect and kinetic disposition on twice-daily dosing in patients with mild or moderate hypertension”, J. Clin. Pharmacol. Nov-Dec; 18(11-12), 519–529.
- Kanikkanan, N., Singh, J. and Ramarao, P. (2000) “Transdermal iontophoretic delivery of Timolol maleate in albino rabbits”, Int. J. Pharm. 20(1-2), 69-79, 197.
- Kanikkanan, N., Singh, J. and Ramarao, P. (2001) “In vitro transdermal delivery of Timolol maleate: effect of age and species”, J. Control Rel. 12(71),99–105, 1.
- Ledger, P.W. (1992) “Skin biological issues in electrically enhanced transdermal delivery”, Adv. Drug Deliv. Rev. 9, 289–307.
- Marro, D., Guy, R.H. and Delgado-Charro, M.B. (2001) “Characteri- zation of the iontophoretic permselectivity properties of human and pig skin”, J. Control Rel. 70, 213–217.
- Molitor, H. and Fernandez, L. (1939) “Studies on iontophoresis I. Experimental studies on the causes and prevention of iontophoretic burns”, Am. J. Med. Sci. 198, 778–785.
- Rosendal, T. (1943) “Studies on the conducting properties of the human skin to direct current”, Acta Physiol. Scand. 5, 130–151.
- Soni, S. and Dixit, W.K. (1994) “Comparison between the iontophoretic and passive transdermal delivery of Timolol maleate across human cadaver skin”, Pharmazie 49(1),73–74.
- Stamatialis, D.F., Rolevink, H.H. and Koops, G.H. (2002) “Controlled transport of Timolol maleate through artificial membranes under passive and iontophoretic delivery”, J. Control Rel. 17(81),335–345, 3.
- Thysman, S., Preat, V. and Roland, M. (1992) “Factors affecting iontophoretic mobility of Metoprolol”, J. Pharm. Sci. 81, 670–675.
- Vedin, J.A., Kristianson, K.J. and Wilhemsson, C.E. (1982) “Pharma- cokinetics of intravenous timolol in patients with acute myocardial infraction and in healthy volunteers”, Eur. J. Clin. Pharmacol. 23, 43.
- Yoshida, N.H. and Roberts, M.S. (1992) “Structure-transport relationships in transdermal iontophoresis”, Adv. Drug Deliv. Rev. 9, 239–246.